9. To participate in Phase 1b all of the following must apply: a) patients must have advanced or metastatic NSCLC; b) patients must have previously received an anti-PD-1 therapy, but either failed to respond or stopped responding after an initial response; c) patients must have measurable disease, i.e., at least one lesion that can be accurately assessed at baseline by computed tomography (CT), magnetic resonance imaging (MRI), or X-ray, that is suitable for repeated assessment.